CD8A and neoplasm: Hickmann et al. show that in immunologically cold tumors, pharmacologic activation of LFA-1 in conjunction with VLA-4 can improve tumor-specific homing and infiltration of CD8+ T cells to promote the antitumor response in a CXCL12-dependent manner, which is further improved in combination with checkpoint blockade [56].